芪白平肺胶囊对慢性阻塞性肺疾病痰瘀阻肺证模型大鼠NO、ET-1及FIB的影响

目的:探讨芪白平肺胶囊(原名金泰胶囊)对慢性阻塞性肺疾病(COPD)痰瘀阻肺证模型大鼠一氧化氮(NO)、内皮素水平(ET-1)、纤维蛋白原(FIB)的影响。方法:采用复合因素造模方法复制COPD痰瘀阻肺证大鼠模型,造模的同时给予芪白平肺胶囊、川芎嗪、硝苯地平,观察大鼠一般状况及NO、ET-1、FIB指标的变化。结果:模型组NO较正常对照组明显下降,ET-1、FIB显著提高(P0.01);硝苯地平组各参数较模型组无差异;川芎嗪组NO、ET-1、FIB较模型组有明显改善(P0.01),但较芪白平肺胶囊高剂量组差异显著(P0.01)。芪白平肺胶囊高剂量组NO、ET-1、FIB与正常组无差异;芪白平肺胶囊低剂量组NO、ET-1、FIB较模型组及芪白平肺胶囊高剂量组均有显著差异(P0.01)。结论:芪白平肺胶囊可使COPD痰瘀阻肺证NO水平升高,降低FIB、ET-1水平。

Effect of Qibai Pingfei Capsule on NO,ET-1 and FIB of rats with COPD of phlegm and blood stasis syndrome

Objective: To discussion the effect of Qibai Pingfei Capsule(formerly known as Jin Tai capsules) on nitric oxide(NO),endothelin(ET-1),fibrinogen(FIB) of rats with COPD of phlegm and blood stasis syndrome.Methods: Complex factor modeling method was adopted,copied rats model with COPD of phlegm and blood stasis syndrome.At the same time,administered Qibai Pingfei Capsule,ligustrazine and nifedipine to the rats,observed the general condition and the changes of NO,ET-1,FIB indexes of rats.Results: The nitric oxide(NO) in the model group decreased obviously than the normal group(P<0.01),the endothelin levels(ET-1),fibrinogen(FIB) in the model group increased significantly than the normal group(P<0.01);The parameters of nifedipine group and model group were without difference;The NO,ET-1,FIB in the ligustrazine group had obviously improved than the model group(P<0.01),but compared with the high-dosage groups of Qibai Pingfei Capsule,there was significant difference(P<0.01).There was no difference of the NO,ET-1,FIB between the high-dosage groups of Qi Qibai Pingfei Capsule and the normal group;There were significantly differences of the NO,ET-1,FIB between the low-doses groups of Qibai Pingfei Capsule and both the model group and high-dosage groups of Qibai Pingfei Capsule(P<0.01).Conclusion: Qibai Pingfei Capsule can effectively increase the NO levels of rats with COPD of phlegm and blood stasis syndrome,reduce the FIB,ET-1 levels.